SEC Form 3 · accession 0001104659-17-005831
MARINUS PHARMACEUTICALS INC · MRNS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael R Dougherty
Director
Period of report
Feb 1, 2017
Accepted (ET)
Feb 1, 2017 · 4:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001267813
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Restricted stockF1 | holding | — | — | — | 9,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock options (right to buy)F2 | $1.23 | holding | — | — | — | — | Feb 1, 2027 | Common Stock | 21,000 | — | D |
Explanation of responses
- F1Each share of restricted stock represents the right to receive, at settlement, one share of common stock. All shares of restricted stock vest on February 1, 2018.
- F2Options to purchase shares of common stock vest monthly over 24 months beginning on February 1, 2018.